NeuroSense Receives FDA Clearance for Pivotal Phase 3 Trial of PrimeC in ALS
核心洞察
NeuroSense Therapeutics received FDA clearance to initiate the pivotal Phase 3 PARAGON trial for PrimeC, a novel combination therapy for amyotrophic lateral sclerosis (搜索) treatment.
The global trial will enroll 300 ALS (搜索) patients in a 2:1 randomization ratio and is powered at over 95% to achieve its primary endpoint.
PrimeC combines ciprofloxacin and celecoxib in an extended-release formulation designed to target multiple ALS (搜索) disease mechanisms including motor neuron (搜索) degeneration and inflammation.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced that the U.S. Food and Drug Administration has completed its review of the Investigational New Drug amendment application and authorized the company to initiate a pivotal Phase 3 clinical trial for PrimeC, its lead drug candidate for treating amyotrophic lateral sclerosis (搜索). The FDA clearance represents a significant regulatory milestone for the late-clinical stage biotechnology company focused on developing treatments for severe neurodegenerative diseases.
The company is preparing for trial initiation and aims to enroll its first patient in the coming months upon securing the strategic resources needed to launch the study. The global Phase 3 trial, designated PARAGON, is powered at over 95% to achieve its primary endpoint and builds upon results from NeuroSense's Phase 2b PARADIGM trial, which demonstrated promising clinical and biomarker outcomes along with a favorable safety and tolerability profile.
Trial Design and Patient Population
Based on prior discussions with the FDA and in line with the agency's recent comments and recommendations, PARAGON will be conducted in the United States and European Union. The trial will include 300 people living with ALS (搜索) randomized in a 2:1 ratio comparing PrimeC to placebo. The prospective, double-blind, 12-month placebo-controlled study includes an open-label extension to evaluate the safety and efficacy of PrimeC.
The trial will employ an adaptive design allowing for interim analyses to optimize sample size and assess early efficacy and futility boundaries. Additional details regarding the PARAGON trial design and timelines will be provided in NeuroSense's upcoming investor webinar scheduled for December 8, 2025.
PrimeC Mechanism and Composition
PrimeC is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. The drug candidate is designed to synergistically target several key mechanisms of ALS (搜索) and Alzheimer's disease (搜索) that contribute to motor neuron (搜索) degeneration, inflammation, iron accumulation, and impaired ribonucleic acid regulation to potentially inhibit disease progression.
"This FDA clearance marks a meaningful advancement for NeuroSense and for people living with ALS (搜索)," stated Alon Ben-Noon, Chief Executive Officer of NeuroSense. "We believe this progress lays a strong foundation for additional achievements across several fronts in the near future. We recognize the significant unmet need of people living with ALS and remain committed to delivering a meaningful therapy through our efforts."
ALS Disease Burden and Market Need
Amyotrophic lateral sclerosis (搜索) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS (搜索) in the United States alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the United States and European Union.
NeuroSense's strategy focuses on developing combined therapies targeting multiple pathways associated with neurodegenerative diseases, including ALS (搜索), Alzheimer's disease (搜索), and Parkinson's disease (搜索). The company believes these conditions represent one of the most significant unmet medical needs, with limited effective therapeutic options currently available for patients.